BNP Paribas Financial Markets Has $8.87 Million Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX

BNP Paribas Financial Markets increased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 107.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 703,664 shares of the company’s stock after buying an additional 364,801 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Amneal Pharmaceuticals worth $8,866,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Spire Wealth Management lifted its stake in Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the period. Intech Investment Management LLC lifted its stake in Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after purchasing an additional 1,159 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the period. Comerica Bank lifted its stake in Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares during the period. Finally, CWM LLC lifted its stake in Amneal Pharmaceuticals by 9.7% during the fourth quarter. CWM LLC now owns 32,070 shares of the company’s stock worth $404,000 after purchasing an additional 2,840 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Down 0.3%

NASDAQ:AMRX opened at $13.71 on Tuesday. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.53 and a 1 year high of $15.42. The firm has a 50 day moving average of $12.76 and a 200-day moving average of $12.99. The stock has a market capitalization of $4.37 billion, a P/E ratio of 36.08 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The company had revenue of $722.52 million during the quarter. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 17.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

AMRX has been the subject of a number of analyst reports. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Truist Financial raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 price target for the company. Finally, Barclays raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.